TCM
INBX

Tybourne Capital Management’s Inhibrx, Inc. Common Stock INBX Stock Holding History

Tybourne Capital Management’s Portfolio INBX Stock Details INBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-95,658
Closed -$2.36M – 43
2022
Q4 		$2.36M Sell
95,658
-550,157
-85% -$16.2M 0.23% 27
2022
Q3 		$11.6M Sell
645,815
-148,867
-19% -$2.68M 1.11% 24
2022
Q2 		$9.02M Hold
794,682
– – 0.65% 25
2022
Q1 		$17.7M Sell
794,682
-233,621
-23% -$5.96M 1.05% 24
2021
Q4 		$44.9M Hold
1,028,303
– – 1.33% 19
2021
Q3 		$34.3M Sell
1,028,303
-71,697
-7% -$2.18M 0.86% 18
2021
Q2 		$30.3M Hold
1,100,000
– – 0.64% 21
2021
Q1 		$22.1M Hold
1,100,000
– – 0.48% 25
2020
Q4 		$36.3M Hold
1,100,000
– – 0.75% 26
2020
Q3 		$19.8M Buy
+1,100,000
New +$19.9M 0.49% 27

Other funds holding INBX

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Tybourne Capital Management's INBX Position: Q1 2023 in Review

Tybourne Capital Management sold out of Inhibrx, Inc. Common Stock (INBX) in Q1 2023, closing a stake of 95,658 shares — an estimated $2.36M sold.

Tybourne Capital Management first reported a position in INBX in Q3 2020 and held it in 10 quarters. The position peaked at $44.9M in Q4 2021. 108 funds tracked by Wall St. Rank hold INBX as of Q1 2023.

  • Tybourne Capital Management reported no remaining Inhibrx, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Tybourne Capital Management sold 95,658 Inhibrx, Inc. Common Stock shares in Q1 2023, an estimated $2.36M.
  • Tybourne Capital Management first reported a position in Inhibrx, Inc. Common Stock in Q3 2020 and held it in 10 quarters.
  • Tybourne Capital Management's Inhibrx, Inc. Common Stock position peaked at $44.9M in Q4 2021.
  • 108 funds tracked by Wall St. Rank held Inhibrx, Inc. Common Stock as of Q1 2023.

Based on Tybourne Capital Management's 13F filing for Q1 2023, filed 15 May 2023.